LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

Concord Asset Management LLC VA grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.3% during the ...

SG Americas Securities LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 31.1% in the fourth quarter, according to the company in its most recent filing with ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised ads and content, ad and content measurement, audience ...

Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its target price hoisted by Stifel Nicolaus from $34.00 to $36.00 in a report issued on Wednesday morning,Benzinga reports. Stifel Nicolaus currently ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for NeuroPace in a report released on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky anticipates that the company ...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...